Floatz logo

Arimidex

Breast Diseases

Fujian Cancer HospitalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Breast Diseases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Incepta Pharmaceuticals Ltd
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Vinorelbine
Sun Yat-sen University
Phase 2BB
Olaparib
AstraZeneca
Phase 2BB
Capecitabine
University of Southern California
Phase 3B

View all 46 →

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →